Predictive biomarkers for bevacizumab in the first line treatment of ovarian cancer

被引：0
|
作者：
Jayson, Gordon [1 ,2 ]
机构：
[1] Christie Hosp, Manchester, Lancs, England
[2] Univ Manchester, Manchester M13 9PL, Lancs, England
来源：
ANGIOGENESIS | 2014年 / 17卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
O-39
引用
收藏
页码：727 / 727
页数：1
相关论文
共 50 条
  • [21] Bevacizumab combined with a taxane and a platinum agent as first-line treatment for advanced-stage ovarian cancer
    Kato, Kazuyoshi
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 30 - 30
  • [22] First line treatment with carboplatin-paclitaxel-bevacizumab in ovarian cancer: retrospective review of a single institute experience
    Bologna, A.
    Garcia-Arias, A.
    Baldi, L.
    Berselli, A.
    Pagano, M.
    Zanelli, F.
    Bisagni, G.
    Gervasi, E.
    Stridi, G.
    Candida, B.
    Romagnani, A.
    Gnoni, R.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [23] GYNECOLOGICAL CANCER First-line bevacizumab for ovarian cancer-new standard of care?
    Banerjee, Susana
    Kaye, Stan B.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (04) : 194 - 196
  • [24] Optimal first-line treatment in ovarian cancer
    Raja, F. A.
    Chopra, N.
    Ledermann, J. A.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 118 - 127
  • [25] First line ovarian cancer treatment: Scanning the horizon
    Lorusso, D.
    Daniele, G.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160
  • [26] Olaparib in combination with bevacizumab compared to bevacizumab monotherapy for the first-line maintenance treatment of advanced ovarian cancer: a cost-effectiveness analysis
    Fan, Lin
    Muston, Dominic
    Elsea, David
    El Moustaid, Fadoua
    Mihai, Adela
    Simmons, Daniel
    McLaurin, Kimmie
    Monberg, Matthew
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 162 : S216 - S217
  • [27] Use of bevacizumab as a first-line treatment for metastatic breast cancer
    Manso, L.
    Moreno, F.
    Marquez, R.
    Castelo, B.
    Arcediano, A.
    Arroyo, M.
    Ballesteros, A. I.
    Calvo, I.
    Echarri, M. J.
    Enrech, S.
    Gomez, A.
    Gonzalez del Val, R.
    Lopez-Miranda, E.
    Martin-Angulo, M.
    Martinez-Janez, N.
    Olier, C.
    Zamora, P.
    [J]. CURRENT ONCOLOGY, 2015, 22 (02) : E51 - E60
  • [28] First-line Treatment of Metastatic Breast Cancer: Focus on Bevacizumab
    Fujii, Teruhiko
    Takahashi, Hiroki
    Matsubayashi, Roka Namoto
    Inoue, Yuka
    Takenaka, Miki
    Toh, Uhi
    Kage, Masayoshi
    Yamana, Hideaki
    Shirouzu, Kazuo
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 583 - 593
  • [29] Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection
    Collinson, Fiona
    Hutchinson, Michelle
    Craven, Rachel A.
    Cairns, David A.
    Zougman, Alexandre
    Wind, Tobias C.
    Gahir, Narinder
    Messenger, Michael P.
    Jackson, Sharon
    Thompson, Douglas
    Adusei, Cybil
    Ledermann, Jonathan A.
    Hall, Geoffrey
    Jayson, Gordon C.
    Selby, Peter J.
    Banks, Rosamonde E.
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (18) : 5227 - 5239
  • [30] Bevacizumab Combination TherapyFor the First-Line Treatment of Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
    Sohita Dhillon
    [J]. Drugs, 2012, 72 : 917 - 930
12345